SIA
COEPW

SkyView Investment Advisors’s Coeptis Therapeutics Warrants COEPW Stock Holding History

SkyView Investment Advisors’s Portfolio COEPW Stock Details COEPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
50,122
– – ﹤0.01% 272
2026
Q1 		$1K Sell
50,122
-5,000
-9% -$60 ﹤0.01% 299
2025
Q4 		$1K Hold
55,122
– – ﹤0.01% 325
2025
Q3 		$1K Hold
55,122
– – ﹤0.01% 316
2025
Q2 		$1K Hold
55,122
– – ﹤0.01% 317
2025
Q1 		$1K Hold
55,122
– – ﹤0.01% 309
2024
Q4 		$1K Hold
55,122
– – ﹤0.01% 278
2024
Q3 		$1K Hold
55,122
– – ﹤0.01% 292
2024
Q2 		$1K Hold
55,122
– – ﹤0.01% 338
2024
Q1 		$1K Hold
55,122
– – ﹤0.01% 323
2023
Q4 		$2K Hold
55,122
– – ﹤0.01% 121
2023
Q3 		$1K Hold
55,122
– – ﹤0.01% 517
2023
Q2 		$4K Hold
55,122
– – ﹤0.01% 511
2023
Q1 		$8K Hold
55,122
– – ﹤0.01% 463
2022
Q4 		$6K Hold
55,122
– – ﹤0.01% 433
2022
Q3 		$2K Buy
55,122
+35,070
+175% +$1.68K ﹤0.01% 514
2022
Q2 		$1K Buy
+20,052
New +$1.51K ﹤0.01% 567

Other funds holding COEPW

RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return

SkyView Investment Advisors's COEPW Position: Q2 2026 in Review

SkyView Investment Advisors held its Coeptis Therapeutics Warrants (COEPW) position steady in Q2 2026 at 50,122 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #272.

SkyView Investment Advisors first reported a position in COEPW in Q2 2022 and has held it in 17 quarters since. The position peaked at $8K in Q1 2023. 3 funds tracked by Wall St. Rank hold COEPW as of Q2 2026.

  • SkyView Investment Advisors held 50,122 shares of Coeptis Therapeutics Warrants worth $0 as of Q2 2026.
  • SkyView Investment Advisors left its Coeptis Therapeutics Warrants share count unchanged in Q2 2026.
  • Coeptis Therapeutics Warrants made up ﹤0.01% of SkyView Investment Advisors's portfolio in Q2 2026, its #272 holding.
  • SkyView Investment Advisors first reported a position in Coeptis Therapeutics Warrants in Q2 2022 and has held it in 17 quarters since.
  • SkyView Investment Advisors's Coeptis Therapeutics Warrants position peaked at $8K in Q1 2023.
  • 3 funds tracked by Wall St. Rank held Coeptis Therapeutics Warrants as of Q2 2026.

Based on SkyView Investment Advisors's 13F filing for Q2 2026, filed 15 Sep 2026.